# First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.

> **NCT01129310** · PHASE2 · COMPLETED · sponsor: **AHS Cancer Control Alberta** · enrollment: 47 (actual)

## Conditions studied

- Gastrointestinal Neoplasm
- Gastric Adenocarcinoma

## Interventions

- **DRUG:** Irinotecan-Capecitabine-Oxaliplatin

## Key facts

- **NCT ID:** NCT01129310
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2018-05-18
- **Final completion:** 2018-05-18
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2019-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01129310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01129310, "First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01129310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*